Maynard Um
-
-
-
-
-
-
-
Leerink Partners stays Outperform on Ovid Therapeutics Inc (OVID) following KCC2 R&D Day
-
-
-
-
-
-
-
Ovid Therapeutics Inc. (OVID) Misses Q3 EPS by 2c
-
-
-
-
-
-
-
Ovid Therapeutics Inc. (OVID) Tops Q2 EPS by 10c
-
-
-
-
-
-
-
Ovid Therapeutics Inc (OVID) PT Lowered to $4 at BTIG
-
-
-
-
-
-
-
B.Riley Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Ovid Therapeutics Inc (OVID)
-
-
-
-
-
-
-
Ovid Therapeutics Inc (OVID) PT Lowered to $1.20 at Citi
-
421,643 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

